{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T00:02:51Z","timestamp":1788998571340,"version":"build-2803163510"},"reference-count":73,"publisher":"MDPI AG","issue":"17","license":[{"start":{"date-parts":[[2022,8,30]],"date-time":"2022-08-30T00:00:00Z","timestamp":1661817600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["IJERPH"],"abstract":"<jats:p>Background: Conventional and newly emerged intravesical modalities have demonstrated prophylactic effectiveness that may improve quality of life (QoL) in non-muscle invasive bladder cancer. The purpose of this study is to analyze existing QoL evidence in patients receiving any form of intravesical therapy. Methods: A PubMed search without time restriction was conducted to identify all relevant studies in accordance with the PICOT question. Additionally, a search was also performed in the Cochrane library database, Internet, and citation. The CONSORT 2010 checklist and STROBE statement checklist were used to evaluate the risk of bias of the included studies. Results: A total of 24 eligible articles were included, which consisted of 11 interventional and 13 observational studies. Intravesical therapy with Bacillus Calmette\u2013Gu\u00e9rin (BCG) or certain chemotherapeutic agents worsens symptom burdens and functional performance during the initial induction phase while continuous improved is observed throughout the maintenance treatment and beyond. Hyperthermia has shown a positive trend in enhancing QoL of patients receiving intravesical chemotherapy, which requires more investigations. However, QoL data were unavailable for other forms of immunotherapy, immune checkpoint inhibitors, electromotive drug administration, and photodynamic therapy. Conclusions: Limited studies suggested the long-term positive impact of intravesical BCG immunotherapy and chemotherapy. However, existing evidence was lacking to clarify the impact of many emerging intravesical therapies that have suggested to be effective and safe, which demands treatment-specific QoL studies.<\/jats:p>","DOI":"10.3390\/ijerph191710825","type":"journal-article","created":{"date-parts":[[2022,8,30]],"date-time":"2022-08-30T21:25:18Z","timestamp":1661894718000},"page":"10825","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":17,"title":["Impact of Effective Intravesical Therapies on Quality of Life in Patients with Non-Muscle Invasive Bladder Cancer: A Systematic Review"],"prefix":"10.3390","volume":"19","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1681-233X","authenticated-orcid":false,"given":"John W.","family":"Yuen","sequence":"first","affiliation":[{"name":"School of Nursing, The Hong Kong Polytechnic University, Hung Hom, Kowloon, Hong Kong SAR, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0095-9137","authenticated-orcid":false,"given":"Ricky W.","family":"Wu","sequence":"additional","affiliation":[{"name":"Biological and Biomedical Sciences, Glasgow Caledonian University, Glasgow G4 OBA, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shirley S.","family":"Ching","sequence":"additional","affiliation":[{"name":"School of Nursing, The Hong Kong Polytechnic University, Hung Hom, Kowloon, Hong Kong SAR, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1723-9646","authenticated-orcid":false,"given":"Chi-Fai","family":"Ng","sequence":"additional","affiliation":[{"name":"S.H. Ho Urology Centre, Department of Surgery, The Chinese University of Hong Kong, Shatin, Hong Kong SAR, China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2022,8,30]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"209","DOI":"10.3322\/caac.21660","article-title":"Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries","volume":"71","author":"Sung","year":"2021","journal-title":"CA Cancer J. Clin."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"S27","DOI":"10.12968\/bjon.2018.27.9.S27","article-title":"Bladder cancer: Overview and disease management. Part 1: Non-muscle-invasive bladder cancer","volume":"27","author":"Anderson","year":"2018","journal-title":"Br. J. Nurs."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1016\/j.eursup.2009.06.010","article-title":"Recurrence, Progression, and Follow-Up in Non\u2013Muscle-Invasive Bladder Cancer","volume":"8","author":"Witjes","year":"2009","journal-title":"Eur. Urol. Suppl."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1177\/153303460600500109","article-title":"Protein profiling of bladder cancer using the 2D-PAGE and SELDI-TOF-MS technique","volume":"5","author":"Langbein","year":"2006","journal-title":"Technol. Cancer Res. Treat."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1080\/0284186X.2017.1369565","article-title":"Retrospective International Study of Cancers of the Urothelial Tract (RISC) Investigators. Radical cystectomy or bladder preservation with radiochemotherapy in elderly patients with muscle-invasive bladder cancer: Retrospective International Study of Cancers of the Urothelial Tract (RISC) Investigators","volume":"57","author":"Boustani","year":"2018","journal-title":"Acta Oncol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"151105","DOI":"10.1016\/j.soncn.2020.151105","article-title":"Supportive Care Needs of Patients on Surveillance and Treatment for Non-Muscle-Invasive Bladder Cancer","volume":"37","author":"McConkey","year":"2021","journal-title":"Semin. Oncol. Nurs."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1590\/S1677-5538.IBJU.2015.0122","article-title":"Are we following the guidelines on non-muscle invasive bladder cancer?","volume":"42","author":"Reis","year":"2016","journal-title":"Int. Braz. J. Urol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"2737","DOI":"10.21037\/tau-20-1333","article-title":"Quality of life in patients undergoing surveillance for non-muscle invasive bladder cancer-a systematic review","volume":"10","author":"Nayak","year":"2021","journal-title":"Transl. Androl. Urol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1111\/bju.14888","article-title":"Health-related quality of life among non-muscle-invasive bladder cancer survivors: A population-based study","volume":"125","author":"Jung","year":"2020","journal-title":"BJU Int."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.1007\/s00520-012-1680-8","article-title":"Quality of life in patients with muscle invasive and non-muscle invasive bladder cancer","volume":"21","author":"Singer","year":"2013","journal-title":"Support Care Cancer"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"139","DOI":"10.3233\/BLC-160051","article-title":"Pursuing Quality in the Application of Bladder Cancer Quality of Life Research","volume":"2","author":"Mohamed","year":"2016","journal-title":"Bladder Cancer"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1186\/s12955-018-1077-6","article-title":"Quality of life in bladder cancer patients receiving medical oncological treatment; a systematic review of the literature","volume":"17","author":"Johansen","year":"2019","journal-title":"Health Qual. Life Outcomes"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1016\/j.juro.2016.12.090","article-title":"Intravesical Therapy for the Treatment of Nonmuscle Invasive Bladder Cancer: A Systematic Review and Meta-Analysis","volume":"197","author":"Chou","year":"2017","journal-title":"J. Urol."},{"key":"ref_14","doi-asserted-by":"crossref","unstructured":"Wang, S., Jin, S., Shu, Q., and Wu, S. (2021). Strategies to Get Drugs across Bladder Penetrating Barriers for Improving Bladder Cancer. Ther. Pharm., 13.","DOI":"10.3390\/pharmaceutics13020166"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1517\/17425247.2016.1100166","article-title":"Advances in intravesical therapy for urinary tract disorders","volume":"13","author":"Tyagi","year":"2016","journal-title":"Expert Opin. Drug Deliv."},{"key":"ref_16","first-page":"CD011935","article-title":"Intravesical Bacillus Calmette-Gu\u00e9rin versus mitomycin C for Ta and T1 bladder cancer","volume":"1","author":"Schmidt","year":"2020","journal-title":"Cochrane Database Syst. Rev."},{"key":"ref_17","first-page":"CD009294","article-title":"Intravesical gemcitabine for non-muscle invasive bladder cancer","volume":"6","author":"Han","year":"2021","journal-title":"Cochrane Database Syst. Rev."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"e002552","DOI":"10.1136\/jitc-2021-002552","article-title":"Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of urothelial cancer","volume":"9","author":"Galsky","year":"2021","journal-title":"J. Immunother. Cancer"},{"key":"ref_19","first-page":"CD012112","article-title":"Intravesical Bacillus Calmette-Gu\u00e9rin with interferon-alpha versus intravesical Bacillus Calmette-Gu\u00e9rin for treating non-muscle-invasive bladder cancer","volume":"3","author":"Shepherd","year":"2017","journal-title":"Cochrane Database Syst. Rev."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"e21","DOI":"10.1016\/j.urolonc.2013.02.010","article-title":"Interferon alfa in the treatment paradigm for non-muscle-invasive bladder cancer","volume":"32","author":"Lamm","year":"2014","journal-title":"Urol. Oncol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"1254","DOI":"10.1111\/j.1464-410X.2008.07968.x","article-title":"Risk-adapted use of intravesical immunotherapy","volume":"102","author":"Braasch","year":"2008","journal-title":"BJU Int."},{"key":"ref_22","first-page":"CD011864","article-title":"Intravesical electromotive drug administration for non-muscle invasive bladder cancer","volume":"9","author":"Jung","year":"2017","journal-title":"Cochrane Database Syst. Rev."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1023\/A:1025144617752","article-title":"Quality of life aspects of bladder cancer: A review of the literature","volume":"12","author":"Botteman","year":"2003","journal-title":"Qual. Life Res."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"221","DOI":"10.3233\/BLC-201510","article-title":"A Systematic Review of Outcome Reporting, Definition and Measurement Heterogeneity in Non-Muscle Invasive Bladder Cancer Effectiveness Trials of Adjuvant, Prophylactic Treatment After Transurethral Resection","volume":"7","author":"Veskimae","year":"2021","journal-title":"Bladder Cancer"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"1","DOI":"10.2147\/ITT.S202006","article-title":"Bacillus Calmette-Gu\u00e9rin (BCG) Therapy for Bladder Cancer: An Update","volume":"9","year":"2020","journal-title":"Immunotargets Ther."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"1111","DOI":"10.1007\/s00345-021-03908-x","article-title":"Adjuvant therapies for non-muscle-invasive bladder cancer: Advances during BCG shortage","volume":"40","author":"Balasubramanian","year":"2022","journal-title":"World J. Urol."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"434","DOI":"10.3109\/02656736.2016.1155761","article-title":"Effects of hyperthermia in neutralising mechanisms of drug resistance in non-muscle-invasive bladder cancer","volume":"32","author":"Dewhirst","year":"2016","journal-title":"Int. J. Hyperth."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"455","DOI":"10.3109\/02656736.2016.1152632","article-title":"Rationale of hyperthermia for radio(chemo)therapy and immune responses in patients with bladder cancer: Biological concepts, clinical data, interdisciplinary treatment decisions and biological tumour imaging","volume":"32","author":"Multhoff","year":"2016","journal-title":"Int. J. Hyperth."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"365","DOI":"10.3233\/BLC-180187","article-title":"Intravesical Radiofrequency-Induced Chemohyperthermia for Carcinoma In Situ of the Urinary Bladder: A Retrospective Multicentre Study","volume":"4","author":"Kajtazovic","year":"2018","journal-title":"Bladder Cancer"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1308\/003588414X13946184901001","article-title":"The effects and effectiveness of electromotive drug administration and chemohyperthermia for treating non-muscle invasive bladder cancer","volume":"96","author":"Slater","year":"2014","journal-title":"Ann. R. Coll. Surg. Engl."},{"key":"ref_31","doi-asserted-by":"crossref","unstructured":"Audisio, A., Buttigliero, C., Delcuratolo, M.D., Parlagreco, E., Audisio, M., Ungaro, A., Di Stefano, R.F., Di Prima, L., Turco, F., and Tucci, M. (2022). New Perspectives in the Medical Treatment of Non-Muscle-Invasive Bladder Cancer: Immune Checkpoint Inhibitors and Beyond. Cells, 11.","DOI":"10.3390\/cells11030357"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1038\/ncpuro0455","article-title":"Transurethral resection of superficial bladder cancer using 5-aminolevulinic acid: Are there any long-term benefits?","volume":"3","year":"2006","journal-title":"Nat. Clin. Pract. Urol."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1111\/iju.13291","article-title":"5-Aminolevulinic acid-mediated photodynamic therapy for bladder cancer","volume":"24","author":"Inoue","year":"2017","journal-title":"Int. J. Urol."},{"key":"ref_34","doi-asserted-by":"crossref","unstructured":"Moher, D., Liberati, A., Tetzlaff, J., Altman, D.G., and PRISMA Group (2009). Preferred reporting items for systematic reviews and meta-analyses: The PRISMA statement. PLoS Med., 6.","DOI":"10.1371\/journal.pmed.1000097"},{"key":"ref_35","first-page":"343","article-title":"A mixed-method study into quality of life for bladder cancer patients","volume":"19","year":"2004","journal-title":"Prof. Nurse"},{"key":"ref_36","doi-asserted-by":"crossref","unstructured":"Hayne, D., Stockler, M., McCombie, S.P., Chalasani, V., Long, A., Martin, A., Sengupta, S., and Davis, I.D. (2015). BCG+MMC trial: Adding mitomycin C to BCG as adjuvant intravesical therapy for high-risk, non-muscle-invasive bladder cancer: A randomised phase III trial (ANZUP 1301). BMC Cancer, 15.","DOI":"10.1186\/s12885-015-1431-6"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"1221","DOI":"10.1016\/S0022-5347(01)66224-4","article-title":"The quality of life during intravesical bacillus Calmette-Guerin therapy","volume":"155","author":"Bohle","year":"1996","journal-title":"J. Urol."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1046\/j.1464-410X.1996.00134.x","article-title":"Quality of life in patients undergoing bacille Calmette-Gu\u00e9rin therapy for superficial bladder cancer","volume":"78","author":"Mack","year":"1996","journal-title":"Br. J. Urol."},{"key":"ref_39","first-page":"143","article-title":"Quality of life in patients undergone oncopreventive intravesical treatment for superficial bladder cancer","volume":"79","author":"Abbona","year":"2007","journal-title":"Arch. Ital. Urol. Androl."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"1756","DOI":"10.1002\/cncr.22556","article-title":"Measuring health-related quality of life outcomes in bladder cancer patients using the Bladder Cancer Index (BCI)","volume":"109","author":"Gilbert","year":"2007","journal-title":"Cancer"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1111\/j.1439-0272.2007.00762.x","article-title":"Bacille Calmette-Gu\u00e9rin intravesical instillation and erectile function: Is there a concern?","volume":"39","author":"Sighinolfi","year":"2007","journal-title":"Andrologia"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1016\/j.radonc.2009.09.018","article-title":"Quadrimodal treatment of high-risk T1 and T2 bladder cancer: Transurethral tumor resection followed by concurrent radiochemotherapy and regional deep hyperthermia","volume":"93","author":"Wittlinger","year":"2009","journal-title":"Radiother. Oncol."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1111\/j.1442-2042.2010.02584.x","article-title":"Maintenance intravesical bacillus Calmette-Gu\u00e9rin instillation for Ta, T1 cancer and carcinoma in situ of the bladder: Randomized controlled trial by the BCG Tokyo Strain Study Group","volume":"17","author":"Koga","year":"2010","journal-title":"Int. J. Urol."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1016\/j.juro.2013.03.097","article-title":"The impact of intravesical gemcitabine and 1\/3 dose Bacillus Calmette-Gu\u00e9rin instillation therapy on the quality of life in patients with nonmuscle invasive bladder cancer: Results of a prospective, randomized, phase II trial","volume":"190","author":"Gontero","year":"2013","journal-title":"J. Urol."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1179\/1973947813Y.0000000126","article-title":"The quality of life in patients during intravesical treatment and correlation with local symptoms","volume":"26","author":"Wei","year":"2014","journal-title":"J. Chemother."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1007\/s11255-015-0940-1","article-title":"Efficacy and safety of pirarubicin combined with hyaluronic acid for non-muscle invasive bladder cancer after transurethral resection: A prospective, randomized study","volume":"47","author":"Huang","year":"2015","journal-title":"Int. Urol. Nephrol."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"e7","DOI":"10.1016\/j.urolonc.2014.09.012","article-title":"Quality of life in patients with non-muscle-invasive bladder cancer: One-year results of a multicentre prospective cohort study","volume":"33","author":"Schmidt","year":"2015","journal-title":"Urol. Oncol."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/j.juro.2015.08.075","article-title":"Randomized Controlled Study of the Efficacy, Safety and Quality of Life with Low Dose bacillus Calmette-Gu\u00e9rin Instillation Therapy for Nonmuscle Invasive Bladder Cancer","volume":"195","author":"Yokomizo","year":"2016","journal-title":"J. Urol."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1080\/21681805.2018.1538162","article-title":"Bladder health in patients treated with BCG instillations for T1G2-G3 bladder cancer\u2014A follow-up five years after the start of treatment","volume":"52","author":"Danielsson","year":"2018","journal-title":"Scand. J. Urol."},{"key":"ref_50","first-page":"9480","article-title":"Health-related quality of life after BCG or MMC induction for non-muscle invasive bladder cancer","volume":"25","author":"Siracusano","year":"2018","journal-title":"Can. J. Urol."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1159\/000493159","article-title":"Value of a Marker Lesion in Non-Muscle-Invasive Bladder Cancer Patients Treated with Interleukin-2 Instillations: A Randomized Controlled Multicentre Trial","volume":"102","author":"Bosschieter","year":"2019","journal-title":"Urol. Int."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/j.eururo.2018.09.005","article-title":"Radiofrequency-induced Thermo-chemotherapy Effect Versus a Second Course of Bacillus Calmette-Gu\u00e9rin or Institutional Standard in Patients with Recurrence of Non-muscle-invasive Bladder Cancer Following Induction or Maintenance Bacillus Calmette-Gu\u00e9rin Therapy (HYMN): A Phase III, Open-label, Randomised Controlled Trial","volume":"75","author":"Tan","year":"2019","journal-title":"Eur. Urol."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1111\/bju.15038","article-title":"CALIBER: A phase II randomized feasibility trial of chemoablation with mitomycin-C vs surgical management in low-risk non-muscle-invasive bladder cancer","volume":"125","author":"Mostafid","year":"2020","journal-title":"BJU Int."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1016\/j.eururo.2021.01.032","article-title":"Quality of Life After Bladder Cancer: A Cross-sectional Survey of Patient-reported Outcomes","volume":"79","author":"Catto","year":"2021","journal-title":"Eur. Urol."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1200\/JCO.20.01665","article-title":"Radical Cystectomy Against Intravesical BCG for High-Risk High-Grade Nonmuscle Invasive Bladder Cancer: Results from the Randomized Controlled BRAVO-Feasibility Study","volume":"39","author":"Catto","year":"2021","journal-title":"J. Clin. Oncol."},{"key":"ref_56","first-page":"e9","article-title":"Quality of life and adverse events in patients with nonmuscle invasive bladder cancer receiving adjuvant treatment with BCG, MMC, or chemohyperthermia","volume":"39","year":"2021","journal-title":"Urol. Oncol."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"887","DOI":"10.1007\/s00520-021-06468-3","article-title":"Intravesical Bacillus Calmette-Guerin treatment-induced sleep quality deterioration in patients with non-muscle invasive bladder cancer: Functional outcome assessment based on a questionnaire survey and actigraphy","volume":"30","author":"Miyake","year":"2022","journal-title":"Support Care Cancer"},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1016\/j.euo.2021.12.006","article-title":"A Phase 1\/2 Single-arm Clinical Trial of Recombinant Bacillus Calmette-Gu\u00e9rin (BCG) VPM1002BC Immunotherapy in Non-muscle-invasive Bladder Cancer Recurrence after Conventional BCG Therapy: SAKK 06\/14","volume":"5","author":"Rentsch","year":"2022","journal-title":"Eur. Urol. Oncol."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"S125","DOI":"10.1016\/S0959-8049(01)00448-8","article-title":"Quality of life research within the EORTC-the EORTC QLQ-C30. European Organisation for Research and Treatment of Cancer","volume":"38","author":"Fayers","year":"2002","journal-title":"Eur. J. Cancer."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"337","DOI":"10.3109\/07853890109002087","article-title":"EQ-5D: A measure of health status from the EuroQol Group","volume":"33","author":"Rabin","year":"2001","journal-title":"Ann. Med."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"2050312116671725","DOI":"10.1177\/2050312116671725","article-title":"SF-36 total score as a single measure of health-related quality of life: Scoping review","volume":"4","author":"Lins","year":"2016","journal-title":"SAGE Open Med."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1093\/jjco\/hyp053","article-title":"Health-related quality of life using SF-8 and EPIC questionnaires after treatment with radical retropubic prostatectomy and permanent prostate brachytherapy","volume":"39","author":"Hashine","year":"2009","journal-title":"Jpn. J. Clin. Oncol."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"1148","DOI":"10.1016\/j.eururo.2014.02.034","article-title":"Validation and reliability testing of the EORTC QLQ-NMIBC24 questionnaire module to assess patient-reported outcomes in non-muscle-invasive bladder cancer","volume":"66","author":"Blazeby","year":"2014","journal-title":"Eur. Urol."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"1764","DOI":"10.1016\/j.juro.2010.01.013","article-title":"Development and validation of the Bladder Cancer Index: A comprehensive, disease specific measure of health related quality of life in patients with localized bladder cancer","volume":"183","author":"Gilbert","year":"2010","journal-title":"J. Urol."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"974","DOI":"10.1200\/JCO.1997.15.3.974","article-title":"Reliability and validity of the Functional Assessment of Cancer Therapy-Breast quality-of-life instrument","volume":"15","author":"Brady","year":"1997","journal-title":"J. Clin. Oncol."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1016\/S0302-2838(02)00403-7","article-title":"The valuation of the International Prostate Symptom Score (IPSS) for use in economic evaluations","volume":"42","author":"Kok","year":"2002","journal-title":"Eur. Urol."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1038\/sj.ijir.3900472","article-title":"Development and evaluation of an abridged, 5-item version of the International Index of Erectile Function (IIEF-5) as a diagnostic tool for erectile dysfunction","volume":"11","author":"Rosen","year":"1999","journal-title":"Int. J. Impot. Res."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/j.eururo.2011.10.004","article-title":"The bladder pain\/interstitial cystitis symptom score: Development, validation, and identification of a cut score","volume":"61","author":"Humphrey","year":"2012","journal-title":"Eur. Urol."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"816","DOI":"10.1111\/j.1442-2042.2008.02121.x","article-title":"Core Lower Urinary Tract Symptom score (CLSS) questionnaire: A reliable tool in the overall assessment of lower urinary tract symptoms","volume":"15","author":"Homma","year":"2008","journal-title":"Int. J. Urol."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1038\/sj.ijir.3900857","article-title":"The International Index of Erectile Function (IIEF): A state-of-the-science review","volume":"14","author":"Rosen","year":"2002","journal-title":"Int. J. Impot. Res."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1038\/s41585-019-0263-6","article-title":"Competitive glucose metabolism as a target to boost bladder cancer immunotherapy","volume":"17","author":"Afonso","year":"2020","journal-title":"Nat. Rev. Urol."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"3874","DOI":"10.1007\/s00330-020-07473-6","article-title":"Bladder cancer: Do we need contrast injection for MRI assessment of muscle invasion? A prospective multi-reader VI-RADS approach","volume":"31","author":"Mastrodicasa","year":"2021","journal-title":"Eur. Radiol."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1016\/j.eururo.2021.02.023","article-title":"Seeing the Unseen: Uncovering Patient-reported Outcomes in Bladder Cancer","volume":"79","author":"Smith","year":"2021","journal-title":"Eur. Urol."}],"container-title":["International Journal of Environmental Research and Public Health"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1660-4601\/19\/17\/10825\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T00:20:35Z","timestamp":1760142035000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1660-4601\/19\/17\/10825"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,8,30]]},"references-count":73,"journal-issue":{"issue":"17","published-online":{"date-parts":[[2022,9]]}},"alternative-id":["ijerph191710825"],"URL":"https:\/\/doi.org\/10.3390\/ijerph191710825","relation":{},"ISSN":["1660-4601"],"issn-type":[{"value":"1660-4601","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,8,30]]}}}